Literature DB >> 32474445

Regulators of G Protein Signaling in Analgesia and Addiction.

Farhana Sakloth1, Claire Polizu1, Feodora Bertherat1, Venetia Zachariou2.   

Abstract

Regulator of G protein signaling (RGS) proteins are multifunctional proteins expressed in peripheral and neuronal cells, playing critical roles in development, physiologic processes, and pharmacological responses. RGS proteins primarily act as GTPase accelerators for activated Gα subunits of G-protein coupled receptors, but they may also modulate signal transduction by several other mechanisms. Over the last two decades, preclinical work identified members of the RGS family with unique and critical roles in intracellular responses to drugs of abuse. New information has emerged on the mechanisms by which RGS proteins modulate the efficacy of opioid analgesics in a brain region- and agonist-selective fashion. There has also been progress in the understanding of the protein complexes and signal transduction pathways regulated by RGS proteins in addiction and analgesia circuits. In this review, we summarize findings on the mechanisms by which RGS proteins modulate functional responses to opioids in models of analgesia and addiction. We also discuss reports on the regulation and function of RGS proteins in models of psychostimulant addiction. Using information from preclinical studies performed over the last 20 years, we highlight the diverse mechanisms by which RGS protein complexes control plasticity in response to opioid and psychostimulant drug exposure; we further discuss how the understanding of these pathways may lead to new opportunities for therapeutic interventions in G protein pathways. SIGNIFICANCE STATEMENT: Regulator of G protein signaling (RGS) proteins are signal transduction modulators, expressed widely in various tissues, including brain regions mediating addiction and analgesia. Evidence from preclinical work suggests that members of the RGS family act by unique mechanisms in specific brain regions to control drug-induced plasticity. This review highlights interesting findings on the regulation and function of RGS proteins in models of analgesia and addiction.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32474445      PMCID: PMC7662521          DOI: 10.1124/mol.119.119206

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  132 in total

1.  RGS14 is a mitotic spindle protein essential from the first division of the mammalian zygote.

Authors:  Luke Martin-McCaffrey; Francis S Willard; Antonio J Oliveira-dos-Santos; David R C Natale; Bryan E Snow; Randall J Kimple; Agnieszka Pajak; Andrew J Watson; Lina Dagnino; Josef M Penninger; David P Siderovski; Sudhir J A D'Souza
Journal:  Dev Cell       Date:  2004-11       Impact factor: 12.270

2.  Differential gene expression in the rat caudate putamen after "binge" cocaine administration: advantage of triplicate microarray analysis.

Authors:  Vadim Yuferov; Thomas Kroslak; K Steven Laforge; Yan Zhou; Ann Ho; Mary Jeanne Kreek
Journal:  Synapse       Date:  2003-06-15       Impact factor: 2.562

3.  RGS mRNA expression in rat striatum: modulation by dopamine receptors and effects of repeated amphetamine administration.

Authors:  S A Burchett; M J Bannon; J G Granneman
Journal:  J Neurochem       Date:  1999-04       Impact factor: 5.372

Review 4.  Regulators of G protein signaling & drugs of abuse.

Authors:  John R Traynor; Richard R Neubig
Journal:  Mol Interv       Date:  2005-02

5.  Regulator of G Protein Signaling 10 (Rgs10) Expression Is Transcriptionally Silenced in Activated Microglia by Histone Deacetylase Activity.

Authors:  Mohammed Alqinyah; Nagini Maganti; Mourad W Ali; Ruchi Yadav; Mei Gao; Ercan Cacan; Han-Rong Weng; Susanna F Greer; Shelley B Hooks
Journal:  Mol Pharmacol       Date:  2016-12-28       Impact factor: 4.436

6.  RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.

Authors:  Stephen J Gold; Chau V Hoang; Bryan W Potts; Gregory Porras; Elsa Pioli; Ki Woo Kim; Agnes Nadjar; Chuan Qin; Gerald J LaHoste; Qin Li; Bernard H Bioulac; Jeffrey L Waugh; Eugenia Gurevich; Rachael L Neve; Erwan Bezard
Journal:  J Neurosci       Date:  2007-12-26       Impact factor: 6.167

7.  RGSZ1, a Gz-selective RGS protein in brain. Structure, membrane association, regulation by Galphaz phosphorylation, and relationship to a Gz gtpase-activating protein subfamily.

Authors:  J Wang; A Ducret; Y Tu; T Kozasa; R Aebersold; E M Ross
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

8.  RGS10-null mutation impairs osteoclast differentiation resulting from the loss of [Ca2+]i oscillation regulation.

Authors:  Shuying Yang; Yi-Ping Li
Journal:  Genes Dev       Date:  2007-07-12       Impact factor: 11.361

9.  The regulator of G-protein signaling RGS16 promotes insulin secretion and β-cell proliferation in rodent and human islets.

Authors:  Kevin Vivot; Valentine S Moullé; Bader Zarrouki; Caroline Tremblay; Arturo D Mancini; Hasna Maachi; Julien Ghislain; Vincent Poitout
Journal:  Mol Metab       Date:  2016-08-26       Impact factor: 7.422

Review 10.  The Role of G-proteins and G-protein Regulating Proteins in Depressive Disorders.

Authors:  Nicolas B Senese; Mark M Rasenick; John R Traynor
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

View more
  1 in total

1.  RGS14 modulates locomotor behavior and ERK signaling induced by environmental novelty and cocaine within discrete limbic structures.

Authors:  Stephanie L Foster; Daniel J Lustberg; Nicholas H Harbin; Sara N Bramlett; John R Hepler; David Weinshenker
Journal:  Psychopharmacology (Berl)       Date:  2021-06-29       Impact factor: 4.415

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.